Product apis-protein-tyrosine-kinase

Home > products > apis> protein-tyrosine-kinase

Catalog	name	Description	price
R-C-1006	PF-04217903 cas:956905-27-4	PF-04217903(PF-4217903)is a novel ATP-competitive small molecule inhibitor of c-Met kinases with the IC50 values from 3.1 nM to 142 nM.PF-04217903(PF-4217903) demonstrated>1000 fold selectivity for c-Met compared with>150 kinases, making it one of the most selective c-Met inhibitors described to date.PF-04217903(PF-4217903)inhibited tumor cell proliferation,survival,migration/invasion in MET amplified cell lines in vitro,and demonstrated marked antitumor activity in tumor models harboring either MET gene amplification or a HGF/c-Met autocrine loop at well-tolerated dose levels in vivo.	price>
R-C-1013	AMG-706 CAS No. 857876-30-3	Motesanib Diphosphate(AMG 706 Diphosphate)is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM,respectively,and has similar activity against Kit,and is approximately 10-fold more selective for VEGFR than PDGFR and Ret.	price>
R-C-1035	ALK inhibitor 2 CAS NO. 761438-38-4	ALK inhibitor 2(compound 18)is a potent pyrimidin ALK inhibitor.ALK inhibitor 2 is a potent inhibitor of testis-specific serine/threonine kinase 2(TSSK2;IC50=37 nM)and focal adhesion kinase(FAK;IC50=5 nM).	price>
R-C-1038	Vandetanib (ZD6474) CAS No. 443913-73-3	Vandetanib(ZD6474)is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay.It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM,respectively.Not sensitive to PDGFRβ,Flt1,Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM.No activity against MEK,CDK2,c-Kit,erbB2,FAK,PDK1,Akt and IGF-1R with IC50 above 10 μM. Vandetanib(ZD6474)increases apoptosis and induces autophagy by increasing the level of reactive oxygen species(ROS).	price>
R-C-1076	Poziotinib (HM781-36B) CAS：1092364-38-9	Poziotinib(HM781-36B)is an orally active,irreversible pan-HER inhibitor,which effectively inhibits EGFRwt,HER-2 and HER-4 with IC50s of 3.2, 5.3 and 23.5 nM, respectively.Poziotinib(HM781-36B)also shows excellent inhibitory activities against mutated EGFRs,including EGFRT790M and EGFRL858R/T790M,with IC50s of 4.2 and 2.2 nM,respectively.Excellent antitumor activity.	price>
R-C-1087	ACTB-1003 CAS：939805-30-8	ACTB-1003 is an oral kinase inhibitor targeting cancer mutations(FGFR inhibition),angiogenesis (inhibition of VEGFR2 and Tie-2)and induces apoptosis (targeting RSK and p70S6K,downstream of PI3 kinase).	price>
R-C-1093	SCR-1481 CAS:1174161-86-4	SCR-1481B1(c-Met inhibitor 2)is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.	price>
R-C-1094	BMS-777607 (BMS 817378) CAS:1025720-94-8	BMS-777607(BMS 817378)is a Met-related inhibitor for c-Met,Axl,Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM,1.8 nM and 4.3 nM in cell-free assays, 40-fold more selective for Met-related targets versus Lck,VEGFR-2,and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases.	price>
R-C-1106	PQ401 CAS：196868-63-0	PQ401 is an inhibitor of insulin-like growth factor 1 receptor(IGF-1R).1 It inhibits autophosphorylation of the recombinant IGF-1R kinase domain(IC50=<1 μM)in a cell-free assay as well as IGF-1-stimulated IGF-1R autophosphorylation in MCF-7 cells(IC50=12μM).PQ401 reduces cell viability of U87MG glioma cells with an IC50 value of 5 μM and induces apoptosis and inhibits cell migration in a concentration-dependent manner.2 It inhibits IGF-1-stimulated proliferation of MCF-7 cells in vitro(IC50=6μM)and reduces tumor growth in an MCNeuA model of murine breast cancer when administered at doses of 50 and 100 mg/kg.1 PQ401 also has antimalarial activity against the P.	price>
R-C-1107	BMS794833 CAS：1174046-72-0	BMS-794833 is a potent ATP competitive inhibitor of Met(cMet)/VEGFR2 with IC50 of 1.7 nM/15 nM,also inhibits Ron,Axl and Flt3 with IC50 of <3 nM;a prodrug of BMS-817378.	price>

...